Point-of-care heart failure platform: where are we now and where are we going to?

References

• Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356.
   PubMed Web of Science ®Google Scholar
• Tsao CW, Aday AW, Almarzooq ZI, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart association. Circulation. 2022;145(8):e153–e639. CIR0000000000001052.
   PubMed Web of Science ®Google Scholar
• GBD. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2017;392(10159):1789–1858. 2018.
   Web of Science ®Google Scholar
• de Boer Ar, Vaartjes I, Gohar A, et al. Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study. ESC Heart Fail. 2022;9(1):363–372.
   PubMedGoogle Scholar
• de Boer Ra, Nayor M, deFilippi CR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018;3(3):215–224.
   PubMedGoogle Scholar
• McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;101161C. https://doi.org/10.1161/CIR.0000000000001063.
   Google Scholar
• Bhambhani V, Kizer JR, Lima JAC, et al. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2018;20(4):651–659.
   PubMedGoogle Scholar
• Liang M, Bian B, Yang Q. Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: a systemic review and meta-analysis. Clin Cardiol. 2022;45(1):5–17.
   PubMedGoogle Scholar
• van Riet Ee, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18(3):242–252.
   PubMed Web of Science ®Google Scholar
• Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–1434.
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Moura B, Metra M, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the heart failure association of the european society of cardiology. Eur J Heart Fail. 2021;23(6):872–881.
   PubMed Web of Science ®Google Scholar
• Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351–366.
   PubMed Web of Science ®Google Scholar
• Greene SJ, Fonarow GC, DeVore AD, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(19):2365–2383.
   PubMed Web of Science ®Google Scholar
• Attia ZI, Kapa S, Lopez-Jimenez F, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019;25(1):70–74.
   PubMed Web of Science ®Google Scholar
• Kashou AH, Medina-Inojosa JR, Noseworthy PA, et al. Artificial intelligence-augmented electrocardiogram detection of left ventricular systolic dysfunction in the general population. Mayo Clin Proc. 2021;96(10):2576–2586.
   PubMedGoogle Scholar
• Adedinsewo D, Carter RE, Attia Z, et al. Artificial intelligence-enabled ecg algorithm to identify patients with left ventricular systolic dysfunction presenting to the emergency department with dyspnea. Circ Arrhythm Electrophysiol. 2020;13(8):e008437.
   PubMedGoogle Scholar
• Bachtiger P, Petri CF, Scott FE, et al. Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG-enabled stethoscope examination in London, UK: a prospective, observational, multicentre study. Lancet Digit Health. 2022;4(2):e117–e125.
   PubMedGoogle Scholar
• Nagendran M, Chen Y, Lovejoy CA, et al. Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. BMJ. 2020;368:m689.
   PubMedGoogle Scholar
• Berezin AE. Biological markers of cardiovascular diseases. Part 4. Diagnostic and prognostic value of biological markers at risk stratification among patients with heart failure. OmniScriptum S.R.L., Chisinau, MD-2012, Republic of Moldova: Lambert Academic Publishing; 2015. p. 329.
   Google Scholar
• Alawieh H, Chemaly TE, Alam S, et al. Towards point-of-care heart failure diagnostic platforms: BNP and NT-proBNP biosensors. Sensors (Basel). 2019;19(22):5003.
   Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing not properly multinational study investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167.
   PubMed Web of Science ®Google Scholar
• Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 2002;144(5):834–839.
   PubMed Web of Science ®Google Scholar
• Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol. 2005;123(3):439–445.
   PubMed Web of Science ®Google Scholar
• Wu AH, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem. 2004;50(5):867–873.
   PubMed Web of Science ®Google Scholar
• Lee-Lewandrowski E, Januzzi JL, Green SM, et al. Multi-center validation of the response biomedical corporation RAMP NT-proBNP assay with comparison to the roche diagnostics GmbH elecsys proBNP assay. Clin Chim Acta. 2007;386(1–2):20–24.
   PubMedGoogle Scholar
• Mongia SK, La’ulu SL, Apple FS, et al. Performance characteristics of the architect brain natriuretic peptide (BNP) assay: a two site study. Clin Chim Acta. 2008;391(1–2):102–105.
   PubMed Web of Science ®Google Scholar
• FDA clears bioMérieux’s VIDAS® NT-proBNP, a high medical value test for diagnosis of heart failure. Press release. bioMérieux Corporate website. 2008 Mar 13. Available at http://www.biomerieux.com/servlet/srt/bio/portail/dynPage?open=PRT_NWS_REL&doc=PRT_NWS_REL_G_PRS_RLS_160&crptprm=ZmlsdGVyPQ.
   Google Scholar
• Tamm NN, Semenov AG, Seferian KR, et al. Measurement of B-type natriuretic peptide by two assays utilizing antibodies with different epitope specificity. Clin Biochem. 2011;44(2–3):257–259.
   PubMedGoogle Scholar
• de Guadiana-Romualdo L G, Ramos-Arenas V, Campos-Rodríguez V, et al. In vitro stability of B-type natriuretic peptide (BNP) in plasma stored under different conditions when measured with the lumipulse® assay. Scand J Clin Lab Invest. 2019;79(6):455–458.
   PubMedGoogle Scholar
• Zaninotto M, Mion MM, Di Serio F, et al. PATHFAST NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay. Clin Chem Lab Med. 2010;48(7):1029–1034. PMID: 20406130.
   PubMed Web of Science ®Google Scholar
• Zugck C, Nelles M, Katus HA, et al. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clin Chem Lab Med. 2006;44(10):1269–1277.
   PubMed Web of Science ®Google Scholar
• Jørgensen B, Bertsch T, Bröker HJ, et al. Multicentre evaluation of a second generation point-of-care assay with an extended range for the determination of N-terminal pro-brain natriuretic peptide. Clin Lab. 2012;58(5–6):515–525. PMID: 22783583.
   PubMedGoogle Scholar
• Khezri BS, Carlsson L, Larsson A. Evaluation of the alere NT-proBNP test for point of care testing. J Clin Lab Anal. 2016;30(4):290–292.
   PubMedGoogle Scholar
• Collin-Chavagnac D, Dehoux M, Schellenberg F, et al., Société Française de Biologie Clinique Cardiac Markers Working Group. Head-to-head comparison of 10 natriuretic peptide assays. Clin Chem Lab Med. 2015;53(11):1825–1837.
   PubMedGoogle Scholar
• Roalfe AK, Taylor CJ, Kelder JC, et al. Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies. ESC Heart Fail. 2021;8(3):2193–2201.
   PubMedGoogle Scholar
• Huusko J, Purmonen T, Toppila I, et al. Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction. ESC Heart Fail. 2020;7(3):1039–1048.
   PubMed Web of Science ®Google Scholar
• Lingervelder D, Koffijberg H, Kusters R, et al. Point-of-care testing in primary care: a systematic review on implementation aspects addressed in test evaluations. Int J Clin Pract. 2019;73(10):e13392.
   PubMedGoogle Scholar
• Ontario Health (Quality). Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as diagnostic tests in adults with suspected heart failure: a health technology assessment. Ont Health Technol Assess Ser. 2021;21(2):1–125. PMID: 34055110; PMCID: PMC8129637.
   Google Scholar
• Berezin AE. Prognostication in different heart failure phenotypes: the role of circulating biomarkers. J Circ Biomark. 2016;5:6.
   PubMedGoogle Scholar
• Alp NJ, Bell JA, Shahi M. A rapid troponin-I-based protocol for assessing acute chest pain. Qjm. 2001;94(12):687–694.
   PubMedGoogle Scholar
• Müller-Bardorff M, Freitag H, Scheffold T, et al. Development and characterization of a rapid assay for bedside determinations of cardiac troponin T. Circulation. 1995;92(10):2869–2875.
   PubMedGoogle Scholar
• Alan HB. Recent advances in point-of-care diagnostics for cardiac markers. Ejifcc. 2014;25(2):170–177. PMID: 27683464; PMCID: PMC4975292.
   PubMedGoogle Scholar
• Apple FS, Fantz CR, Collinson PO. IFCC committee on clinical application of cardiac bio-markers. implementation of high-sensitivity and point-of-care cardiac troponin assays into practice: some different thoughts. Clin Chem. 2021;67(1):70–78.
   PubMedGoogle Scholar
• Ramparany L, Ramirez J, Nizou JY, et al. Evaluation of four rapid immunochromatographic tests for the detection of cardiac troponin I. Clin Vaccine Immunol. 2011;18(3):414–417.
   PubMedGoogle Scholar
• Body R, Morris N, Collinson P. Single test rule-out of acute myocardial infarction using the limit of detection of a new high-sensitivity troponin I assay. Clin Biochem. 2020;78:4–9.
   PubMedGoogle Scholar
• Melentiev PN, Son LV, Kudryavtsev DS, et al. Ultrasensitive detection and imaging of single cardiac troponin-T molecules. ACS Sens. 2020;5(11):3576–3583.
   PubMedGoogle Scholar
• Zhang B, Morales AW, Peterson R, et al. Label-free detection of cardiac troponin I with a photonic crystal biosensor. Biosens Bioelectron. 2014;58:107–113.
   PubMedGoogle Scholar
• Kozinski M, Krintus M, Kubica J, et al. High-sensitivity cardiac troponin assays: from improved analytical performance to enhanced risk stratification. Crit Rev Clin Lab Sci. 2017;54(3):143–172.
   PubMed Web of Science ®Google Scholar
• Gao S, Li J. Development of a novel homogeneous nanoparticle-based assay for rapid and high-throughput quantitation of the sST2 protein in human serum. Int J Nanomedicine. 2020;15:10539–10546.
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Egger M, Gegenhuber A, et al. Analytical and clinical evaluation of a rapid quantitative lateral flow immunoassay for measurement of soluble ST2 in human plasma. Clin Chim Acta. 2015;451(Pt B):310–315.
   PubMedGoogle Scholar
• Dikme R, Padak M, Işık M, et al. Soluble ST2 as a potential biomarker in pericardial fluid of coronary artery patientsю braz. J Cardiovasc Surg. 2021;36(5):677–684.
   Google Scholar
• McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12(4):200–210.
   PubMed Web of Science ®Google Scholar
• Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(11):1054–1060.
   PubMed Web of Science ®Google Scholar
• Gruson D, Mancini M, Ahn SA, et al. Measurement of Galectin-3 with the ARCHITECT assay: clinical validity and cost-effectiveness in patients with heart failure. Clin Biochem. 2014;47(12):1006–1009.
   PubMed Web of Science ®Google Scholar
• Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009;30(9):1057–1065.
   PubMed Web of Science ®Google Scholar
• Banerjee S, McCormack S. Natriuretic peptide testing for monitoring of heart failure therapy: a review of clinical effectiveness, clinical utility, cost-effectiveness, and guidelines [internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug 19 PMID: 31693326.
   Google Scholar
• Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488–504.
   PubMed Web of Science ®Google Scholar
• Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297–3317.
   PubMed Web of Science ®Google Scholar
• Barutaut M, Fournier P, Peacock WF, et al. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. Acta Cardiol. 2020;75(8):739–747.
   PubMed Web of Science ®Google Scholar
• Alhejily WA. High sensitivity troponins in patients with elevated prohormone of beta natriuretic peptide and acute heart failure (HIGH TRIP trial). Sci Rep. 2022;12(1):1838.
   PubMedGoogle Scholar
• Topf A, Mirna M, Ohnewein B, et al. The diagnostic and therapeutic value of multimarker analysis in heart failure. An approach to biomarker-targeted therapy. Front Cardiovasc Med. 2020;7:579567.
   PubMedGoogle Scholar
• Pufulete M, Maishman R, Dabner L, et al. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. Health Technol Assess. 2017;21(40):1–150.
   PubMed Web of Science ®Google Scholar
• Mark DB, Cowper PA, Anstrom KJ, et al. Economic and quality-of-life outcomes of natriuretic peptide-guided therapy for heart failure. J Am Coll Cardiol. 2018;72(21):2551–2562.
   PubMedGoogle Scholar
• Logan JK, Mentz RJ. Targeting natriuretic peptide levels in heart failure with therapy: does “X” Really mark the spot? Curr Heart Fail Rep. 2019;16(6):250–256.
   PubMedGoogle Scholar
• Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017;318(8):713–720.
   PubMed Web of Science ®Google Scholar
• Ibrahim NE, Januzzi JL Jr. The future of biomarker-guided therapy for heart failure after the guiding evidence-based therapy using biomarker intensified treatment in heart failure (GUIDE-IT) study. Curr Heart Fail Rep. 2018;15(2):37–43.
   PubMedGoogle Scholar
• Sanders-van Wijk S, van Asselt Ad, Rickli H, et al. TIME-CHF investigators. cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (trial of intensified versus standard medical therapy in elderly patients with congestive heart failure). JACC Heart Fail. 2013;1(1):64–71.
   PubMed Web of Science ®Google Scholar
• Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol. 2009;55(1):53–60.
   PubMed Web of Science ®Google Scholar
• Ouwerkerk W, Zwinderman AH, Ng LL, et al. Biomarker-Guided versus guideline-based treatment of patients with heart failure: results from BIOSTAT-CHF. J Am Coll Cardiol. 2018;71(4):386–398.
   PubMed Web of Science ®Google Scholar
• Felker GM, Hasselblad V, Hernandez AF, et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422–430.
   PubMed Web of Science ®Google Scholar
• Rocca HP B-L, Bektas S. Biomarker guided therapy in chronic heart failure. Card Fail Rev. 2015;1(2):96–101.
   PubMedGoogle Scholar
• Huet F, Nicoleau J, Dupuy AM, et al. STADE-HF (sST2 As a help for management of HF): a pilot study. ESC Heart Fail. 2020;7(2):774–778.
   PubMed Web of Science ®Google Scholar
• Chen H, Chen C, Fang J, et al. Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis. Heart Fail Rev. 2020;25(2):331–341.
   PubMedGoogle Scholar
• Wu C, Lv Z, Li X, et al. Galectin-3 in predicting mortality of heart failure: a systematic review and meta-analysis. Heart Surg Forum. 2021;24(2):E327–E332.
   PubMed Web of Science ®Google Scholar
• Srivatsan V, George M, Shanmugam E. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? Eur J Prev Cardiol. 2015;22(9):1096–1110.
   PubMed Web of Science ®Google Scholar
• Motiwala SR, Szymonifka J, Belcher A, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15(10):1157–1163.
   PubMed Web of Science ®Google Scholar
• Hwang R, Bruning J, Morris NR, et al. Home-based telerehabilitation is not inferior to a centre-based program in patients with chronic heart failure: a randomised trial. J Physiother. 2017;63(2):101–107.
   PubMed Web of Science ®Google Scholar
• Piotrowicz E, Piepoli MF, Jaarsma T, et al. Telerehabilitation in heart failure patients: the evidence and the pitfalls. Int J Cardiol. 2016;220:408–413.
   PubMed Web of Science ®Google Scholar
• Sano M, Majima T. Development of a home-based nursing intervention model for patients with heart failure: a qualitative feasibility study. Inquiry. 2021;58:469580211067448.
   PubMedGoogle Scholar
• Desai AS, Maclean T, Blood AJ, et al. Remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2020;5(12):1430–1434.
   PubMedGoogle Scholar
• Karamat S, Ahmed SA, Naqvi SJ. An excellent model to increase adherence to guideline-directed medical therapy-with far-reaching implications. JAMA Cardiol. 2021;6(6):726.
   PubMedGoogle Scholar
• Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018;392(10152):1047–1057.
   PubMed Web of Science ®Google Scholar
• Bhatt AS, Varshney AS, Nekoui M, et al. Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. Eur J Heart Fail. 2021;23(7):1191–1201.
   PubMedGoogle Scholar
• Hill L, Lambrinou E, Antoniou S. Optimizing evidence-based heart failure medication: every contact counts. Eur J Heart Fail. 2021;23(7):1202–1204.
   PubMedGoogle Scholar
• Brouwers RW, Kraal JJ, Traa SC, et al. Effects of cardiac telerehabilitation in patients with coronary artery disease using a personalised patient-centred web application: protocol for the smartcare-CAD randomised controlled trial. BMC Cardiovasc Disord. 2017;17(1):46.
   PubMedGoogle Scholar
• Piotrowicz E. The management of patients with chronic heart failure: the growing role of e-Health. Expert Rev Med Devices. 2017;14(4):271–277.
   PubMed Web of Science ®Google Scholar
• Spindler H, Leerskov K, Joensson K, et al. Conventional rehabilitation therapy versus telerehabilitation in cardiac patients: a comparison of motivation, psychological distress, and quality of life. Int J Environ Res Public Health. 2019;16(3):512.
   Google Scholar
• Frederix I, Vanhees L, Dendale P, et al. A review of telerehabilitation for cardiac patients. J Telemed Telecare. 2015;21(1):45–53.
   PubMed Web of Science ®Google Scholar
• Cartwright M, Hirani SP, Rixon L, et al. Whole systems demonstrator evaluation team effect of telehealth on quality of life and psychological outcomes over 12 months (whole systems demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial. BMJ. 2013;346:f653.
   PubMed Web of Science ®Google Scholar
• Fiani B, Siddiqi I, Lee SC, et al. Telerehabilitation: development, application, and need for increased usage in the COVID-19 era for patients with spinal pathology. Cureus. 2020;12(9):e10563.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Dalal H, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2010;1:CD007130.
   PubMed Web of Science ®Google Scholar
• Skov Schacksen C, Henneberg NC, Muthulingam JA, et al. Effects of telerehabilitation interventions on heart failure management (2015-2020): scoping review. JMIR Rehabil Assist Technol. 2021;8(4):e29714.
   PubMedGoogle Scholar
• Piotrowicz E, Mierzyńska A, Banach M, et al. Quality of life in heart failure patients undergoing hybrid comprehensive telerehabilitation versus usual care - results of the telerehabilitation in heart failure patients (TELEREH-HF) randomized clinical trial. Arch Med Sci. 2020;17(6):1599–1612.
   PubMedGoogle Scholar
• Peng X, Su Y, Hu Z, et al. Home-based telehealth exercise training program in Chinese patients with heart failure: a randomized controlled trial. Medicine (Baltimore). 2018;97(35):e12069.
   PubMed Web of Science ®Google Scholar
• Chen YW, Wang CY, Lai YH, et al. Home-based cardiac rehabilitation improves quality of life, aerobic capacity, and readmission rates in patients with chronic heart failure. Medicine (Baltimore). 2018;97(4):e9629.
   PubMed Web of Science ®Google Scholar
• Jamal NE, Abi-Saleh B, Isma’eel H. Advances in telemedicine for the management of the elderly cardiac patient. J Geriatr Cardiol. 2021;18(9):759–767.
   PubMedGoogle Scholar
• Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev. 2019;1(1):CD003331.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Walker S, Ciani O, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess. 2019;23(25):1–98.
   Web of Science ®Google Scholar
• Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014; 1(4):CD003331. Update in 2019 Jan 29.
   Google Scholar
• Harwood AE, Russell S, Okwose NC, et al. A systematic review of rehabilitation in chronic heart failure: evaluating the reporting of exercise interventions. ESC Heart Fail. 2021;8(5):3458–3471.
   PubMedGoogle Scholar
• Abraham LN, Sibilitz KL, Berg SK, et al. Exercise-based cardiac rehabilitation for adults after heart valve surgery. Cochrane Database Syst Rev. 2021;5(5):CD010876.
   PubMedGoogle Scholar
• Bader F, Manla Y, Atallah B, et al. Heart failure and COVID-19. Heart Fail Rev. 2021;26(1):1–10.
   PubMedGoogle Scholar